Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Birtamimab · NEOD001

Monoclonal antibody · Antagonist of misfolded light chain aggregates and amyloid fibrils · developed by Prothena Biosciences

Phase 3 Most advanced trial (none active)
PRTA Developer
2 Registered trials

What is Birtamimab?

Birtamimab (NEOD001) is a humanized IgG1 monoclonal antibody that binds misfolded light chain aggregates and amyloid fibrils. It is studied in patients with light chain (AL) amyloidosis, where it aims to prevent amyloid deposit formation and promote their clearance from organs.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NEOD001
Drug type
Monoclonal antibody
Targets
misfolded light chain aggregates and amyloid fibrils
Mechanism
Antagonist of misfolded light chain aggregates and amyloid fibrils
Pathways
amyloid deposit formation and clearance
Therapy area
Oncology
Developer
Prothena Biosciences Ltd. (PRTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
VXQ2SK8I3P

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04973137 Phase 3 Light Chain (AL) Amyloidosis Terminated PRTA
NCT02312206 Phase 3 Primary Systemic (AL) Amyloidosis Terminated PRTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Light Chain (AL) AmyloidosisPrimary Systemic (AL) Amyloidosis

More from Prothena Biosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRTA page.

Follow PRTA, the company behind Birtamimab

See PRTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.